This bill amends the Public Health Code to specifically address the controlled substance xylazine, updating key definitions related to its administration, delivery, and licit use. It establishes that xylazine is to be used solely for legitimate medical purposes and introduces penalties for illicit use, possession, and distribution, categorizing these offenses as felonies punishable by up to five years in prison or fines up to $15,000. The bill also clarifies the responsibilities of practitioners regarding controlled substances, emphasizing adherence to legitimate therapeutic or scientific purposes when dispensing xylazine. Additionally, it includes provisions to protect individuals seeking medical assistance in drug-related emergencies from legal repercussions for possessing small amounts of controlled substances, including xylazine.

Moreover, the bill expands the definitions surrounding drug-related offenses, including a new definition for "drug overdose" that encompasses conditions resulting from the use of controlled substances like xylazine. It establishes increased penalties for the fraudulent acquisition of controlled substances and allows courts to mandate rehabilitative services for offenders. The definition of "drug paraphernalia" is also broadened to include items specifically designed for xylazine use, with legal consequences outlined for selling such paraphernalia. The bill aims to enhance the regulation of xylazine, address concerns surrounding drug use, and provide a clearer legal framework for both practitioners and individuals seeking help.

Statutes affected:
House Introduced Bill: 333.7103